Nath Bio-Genes (India) Limited (NATHBIOGEN) - Net Assets
Based on the latest financial reports, Nath Bio-Genes (India) Limited (NATHBIOGEN) has net assets worth Rs6.80 Billion INR (≈ $73.52 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs10.14 Billion ≈ $109.68 Million USD) and total liabilities (Rs3.34 Billion ≈ $36.16 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Nath Bio-Genes (India) Limited asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs6.80 Billion |
| % of Total Assets | 67.04% |
| Annual Growth Rate | 22.57% |
| 5-Year Change | 5.07% |
| 10-Year Change | 431.22% |
| Growth Volatility | 62.02 |
Nath Bio-Genes (India) Limited - Net Assets Trend (2012–2025)
This chart illustrates how Nath Bio-Genes (India) Limited's net assets have evolved over time, based on quarterly financial data. Also explore NATHBIOGEN asset base for the complete picture of this company's asset base.
Annual Net Assets for Nath Bio-Genes (India) Limited (2012–2025)
The table below shows the annual net assets of Nath Bio-Genes (India) Limited from 2012 to 2025. For live valuation and market cap data, see NATHBIOGEN market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | Rs6.44 Billion ≈ $69.69 Million |
+5.65% |
| 2024-03-31 | Rs6.10 Billion ≈ $65.96 Million |
+6.41% |
| 2023-03-31 | Rs5.73 Billion ≈ $61.99 Million |
+5.76% |
| 2022-03-31 | Rs5.42 Billion ≈ $58.61 Million |
-11.63% |
| 2021-03-31 | Rs6.13 Billion ≈ $66.32 Million |
+9.98% |
| 2020-03-31 | Rs5.58 Billion ≈ $60.30 Million |
+9.86% |
| 2019-03-31 | Rs5.08 Billion ≈ $54.89 Million |
+8.17% |
| 2018-03-31 | Rs4.69 Billion ≈ $50.75 Million |
+241.04% |
| 2017-03-31 | Rs1.38 Billion ≈ $14.88 Million |
+13.42% |
| 2016-03-31 | Rs1.21 Billion ≈ $13.12 Million |
+13.22% |
| 2015-03-31 | Rs1.07 Billion ≈ $11.59 Million |
+31.01% |
| 2014-03-31 | Rs817.78 Million ≈ $8.84 Million |
+42.29% |
| 2013-03-31 | Rs574.74 Million ≈ $6.22 Million |
+25.69% |
| 2012-03-31 | Rs457.28 Million ≈ $4.95 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Nath Bio-Genes (India) Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 3274.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Rs4.76 Billion | 73.91% |
| Common Stock | Rs190.04 Million | 2.95% |
| Other Comprehensive Income | Rs156.10 Million | 2.42% |
| Other Components | Rs1.33 Billion | 20.72% |
| Total Equity | Rs6.44 Billion | 100.00% |
Nath Bio-Genes (India) Limited Competitors by Market Cap
The table below lists competitors of Nath Bio-Genes (India) Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
JD Sports Fashion PLC
LSE:JD
|
$40.30 Million |
|
RFTech Co. Ltd
KQ:061040
|
$40.31 Million |
|
Pyung Hwa Hldg
KO:010770
|
$40.32 Million |
|
TradeDoubler AB
ST:TRAD
|
$40.33 Million |
|
Remsons Industries Limited
NSE:REMSONSIND
|
$40.28 Million |
|
NHN Bugs Corp
KQ:104200
|
$40.27 Million |
|
Brunswick Exploration Inc
V:BRW
|
$40.26 Million |
|
Kristal Kola ve Mesrubat Sanayi Ticaret AS
IS:KRSTL
|
$40.25 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Nath Bio-Genes (India) Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 6,099,187,000 to 6,443,871,000, a change of 344,684,000 (5.7%).
- Net income of 385,998,000 contributed positively to equity growth.
- Dividend payments of 38,008,000 reduced retained earnings.
- Other comprehensive income decreased equity by 3,305,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs386.00 Million | +5.99% |
| Dividends Paid | Rs38.01 Million | -0.59% |
| Other Comprehensive Income | Rs-3.31 Million | -0.05% |
| Other Changes | Rs-1.00K | -0.0% |
| Total Change | Rs- | 5.65% |
Book Value vs Market Value Analysis
This analysis compares Nath Bio-Genes (India) Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.58x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 6.86x to 0.58x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-03-31 | Rs28.57 | Rs196.01 | x |
| 2013-03-31 | Rs35.91 | Rs196.01 | x |
| 2014-03-31 | Rs51.10 | Rs196.01 | x |
| 2015-03-31 | Rs66.94 | Rs196.01 | x |
| 2016-03-31 | Rs75.80 | Rs196.01 | x |
| 2017-03-31 | Rs85.97 | Rs196.01 | x |
| 2018-03-31 | Rs276.18 | Rs196.01 | x |
| 2019-03-31 | Rs267.09 | Rs196.01 | x |
| 2020-03-31 | Rs293.42 | Rs196.01 | x |
| 2021-03-31 | Rs322.71 | Rs196.01 | x |
| 2022-03-31 | Rs285.19 | Rs196.01 | x |
| 2023-03-31 | Rs301.61 | Rs196.01 | x |
| 2024-03-31 | Rs320.94 | Rs196.01 | x |
| 2025-03-31 | Rs336.21 | Rs196.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Nath Bio-Genes (India) Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 5.99%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 10.58%
- • Asset Turnover: 0.36x
- • Equity Multiplier: 1.59x
- Recent ROE (5.99%) is below the historical average (11.12%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 20.12% | 7.42% | 1.03x | 2.62x | Rs46.28 Million |
| 2013 | 20.44% | 8.53% | 0.87x | 2.75x | Rs59.98 Million |
| 2014 | 29.72% | 12.83% | 1.00x | 2.32x | Rs161.26 Million |
| 2015 | 23.71% | 13.70% | 0.82x | 2.11x | Rs146.84 Million |
| 2016 | 11.68% | 8.74% | 0.61x | 2.20x | Rs20.37 Million |
| 2017 | 11.83% | 9.59% | 0.59x | 2.10x | Rs25.24 Million |
| 2018 | 6.27% | 15.35% | 0.34x | 1.22x | Rs-175.05 Million |
| 2019 | 7.57% | 16.67% | 0.36x | 1.27x | Rs-123.25 Million |
| 2020 | 9.05% | 18.04% | 0.38x | 1.31x | Rs-52.78 Million |
| 2021 | 9.08% | 18.11% | 0.39x | 1.29x | Rs-56.66 Million |
| 2022 | -12.42% | -24.19% | 0.38x | 1.37x | Rs-1.22 Billion |
| 2023 | 6.11% | 11.62% | 0.38x | 1.38x | Rs-223.06 Million |
| 2024 | 6.50% | 16.01% | 0.28x | 1.44x | Rs-213.73 Million |
| 2025 | 5.99% | 10.58% | 0.36x | 1.59x | Rs-258.39 Million |
Industry Comparison
This section compares Nath Bio-Genes (India) Limited's net assets metrics with peer companies in the Agricultural Inputs industry.
Industry Context
- Industry: Agricultural Inputs
- Average net assets among peers: $13,370,134,277
- Average return on equity (ROE) among peers: 16.89%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Nath Bio-Genes (India) Limited (NATHBIOGEN) | Rs6.80 Billion | 20.12% | 0.49x | $40.28 Million |
| Agro Phos India Limited (AGROPHOS) | $469.69 Million | 12.41% | 0.80x | $6.93 Million |
| Astec LifeSciences Limited (ASTEC) | $2.03 Billion | 17.62% | 1.27x | $167.40 Million |
| Bayer Cropscience Limited (BAYERCROP) | $25.24 Billion | 25.56% | 0.72x | $2.32 Billion |
| Best Agrolife Limited (BESTAGRO) | $577.23 Million | 0.02% | 0.90x | $68.89 Million |
| Bhagiradha Chemicals & Industries Limited (BHAGCHEM) | $465.11 Million | 4.24% | 1.68x | $371.49 Million |
| Bharat Rasayan Limited (BHARATRAS) | $7.27 Billion | 22.53% | 0.25x | $248.90 Million |
| Bohra Industries Limited (BOHRAIND) | $340.42 Million | 12.70% | 2.21x | $2.15 Million |
| Bombay Super Hybrid Seeds Limited (BSHSL) | $563.36 Million | 29.79% | 1.36x | $111.73 Million |
| Chambal Fertilizers & Chemicals Limited (CHAMBLFERT) | $72.58 Billion | 17.58% | 0.59x | $1.90 Billion |
| Coromandel International Limited (COROMANDEL) | $24.16 Billion | 26.44% | 2.30x | $6.32 Billion |
About Nath Bio-Genes (India) Limited
Nath Bio-Genes (India) Limited engages in the production, processing, and marketing of hybrid and GM seeds in India and internationally. It operates in two segments, Agricultural Activities and Trading Activities. The company offers fiber and oil seeds, including cotton and mustard; seeds for field crops, such as bajra, corn, paddy, wheat, and jowar; fruit seeds; and seeds for vegetables comprisi… Read more